CYSTISTAT® FOR SURGEONS

Cystistat^® is a medical device for the temporary replacement of the glycosaminoglycan (GAG) layer in the bladder.

The GAG layer is deficient in cystitis; Cystistat^® is instilled into the bladder to alleviate symptoms associated with cystitis. Cystistat^® is supplied in a glass vial. Cystistat^® is a sterile sodium hyaluronate solution containing 40 mg/50 mL sodium hyaluronate. This sterile solution is used for instillation into the bladder. Cystistat^® contains a highly purified sodium salt of hyaluronic acid (HA) produced by fermentation. HA plays a vital role in extracellular matrix homeostasis, wound healing, and tissue regeneration.¹⁰Cystistat^® has a wide range of published papers supporting the treatment of cystitis.

BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS (BPS/IC)

The cause of this disorder is still not clear but different hypotheses include subclinical infection, inflammation, mast cell activation and autoimmune mechanisms.²

BPS/IC is a chronic inflammation of the bladder wall. It is not believed to be caused by bacteria and does not respond to conventional antibiotic treatment.³

BPS/IC is found in all countries around the world and in all races. It is mainly found in women but many men may in fact be underdiagnosed due to a misdiagnosis.⁴

RECURRENT BACTERIAL CYSTITIS (RBC)

Bacterial cystitis is an inflammation of the bladder caused by bacteria entering the bladder via the urethra.

Escherichia Coli are the most common type of bacteria responsible for causing urinary tract infections (UTI).³

If repeated recurrent bacterial infections occur i.e. one infection every three months or more frequently, this is classed as recurrent bacterial cystitis (RBC).³

RADIATION-INDUCED CYSTITIS (RIC)

Haemorrhagic cystitis is a frequent complication in patients receiving⁵

Radiation therapy to the pelvic area (radiation-induced cystitis (RIC))
Administration of treatments directly into the bladder (e.g. bacillus Calmette-Guérin)

Haemorrhagic cystitis has been defined as ‘the presence of sustained haematuria and lower urinary tract symptoms (e.g. dysuria, frequency, urgency) in the absence of active tumour and other conditions’.⁵